ILK and cancer: Moreover, the effectiveness of oral T315 to disrupt this regulatory loop and reverse mesenchymal phenotype in vivo provides a proof-of-concept that inhibition of ILK by small-molecule agents represents a therapeutically relevant strategy to reduce the aggressive phenotype of cancer cells.